Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film
7.7.2020 15:00:00 EEST | Business Wire | Press release
Cybin Corp. (“Cybin” or the “Company”), Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, is pleased to announce that it has entered into a feasibility agreement with IntelGenx Corp. (OTCQB:IGXT; TSX-V:IGX) (“IntelGenx”) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals.
“We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” said Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”
“Cybin's intention with an orally-dissolving psilocybin film is to bypass the digestive system, which will provide faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief,” added Cybin’s Chief Executive Officer, Paul Glavine.
Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “This partnership exemplifies both the versatility and clinical advantages of our VersaFilm® technology platform. In addition to offering patients a convenient method of administration, our technology offers superior drug bioavailability, which decreases both the amount of active pharmaceutical ingredient required per dose, as well as time to onset of action, which are paramount when treating distressing conditions such as anxiety. We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.”
About Cybin
Cybin is a mushroom life sciences company advancing psychedelic and nutraceutical-based products. The Company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the Company is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical delivery films.
IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot-and commercial-scale production. For more information, visit www.intelgenx.com.
Forward Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the ability to receive regulatory approvals, the bioavailability of the film, the potential safety and efficacy of psilocybin administered in an orally-dissolving film, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005296/en/
Contact information
Sara Brittany Somerset
Email: sarabrittany@cybin.com
www.cybin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses10.9.2026 14:45:00 EEST | Press release
Johnson & Johnson (NYSE: JNJ) today announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week,*** a new reusable contact lens featuring proprietary MAX technologies designed to deliver superior comfort and visual clarity, even at day 14.*†i¥1 The lens will be rolled out in select European countries later this year with wider market rollout in 2027. Globally, 140 million people wear contact lenses, with one in two choosing a reusable lens,2 and comfort remains their leading priority.3 With the continued rise in everyday use of digital devices and exposure to blue-violet light, more demands are being placed on patients’ eyes, often leading to reduced visual clarity and symptoms of dryness.4,5,6,7 ACUVUE OASYS MAX 2-Week brings Johnson & Johnson’s advanced MAX contact lens technologies to reusable contact lens wearers, helping address their evolving vision, comfort, and digital lifestyle needs. “People who choose reusable contact lenses should not have to compromise on comfort
Virtual Installation The Kuutar Garden by Jakob Kudsk Steensen Opens in Oulu, Finland, in September10.9.2026 14:37:00 EEST | Press release
Deep underneath the city centre of Oulu, Danish artist Jakob Kudsk Steensen’s site-specific installation The Kuutar Garden comes to life on 18 September as part of the Oulu2026 European Capital of Culture programme, featuring musical collaborations with Danny L Harle and vocalist yeule. “The Kuutar Garden evokes a new ecological reality, unrooted from our physical boundaries, into a rhythmic and ghost-like world nurtured by a moonlight illuminated botanical garden. I hope audiences feel connected to the emergence of new worlds, and the caring of overlooked plant life,” says Steensen. The Kuutar Garden emerges from over four years of ecological fieldwork within the Botanical Garden of the University of Oulu, one of the world's northernmost botanic gardens, where Steensen bore witness to subarctic winters set against the artificial glow of greenhouse architecture. From this encounter, Steensen has conjured a virtual replica of that architecture, carrying audiences into an otherworldly re
New Circularity Data: Nine Out of Ten Returned Items Lose Value for Retailers10.9.2026 14:33:00 EEST | Press release
New research from ReBound Returns and Advanced Supply Chain (ASC) has revealed a gap between retailers’ circularity ambitions and the value they are recovering from returned products. The Circularity Index, based on research among 150 senior leaders at mid-to-large UK and European retailers, found that 86% have an established approach to circularity in returns, with practices including resale, refurbishment, repair and recycling regularly used across the business. For 27%, circularity is a core part of how returns are managed. However, translating those strategies into commercial value remains difficult. On average, 12% of returned items generate no value, while only 9% of retailers resell more than half of their returned products at full price. There is also a significant opportunity still to be captured. 82% of retailers believe that up to half of their returned stock could generate additional value through enhanced recommerce strategies, while 62% already make regular efforts to rec
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 14:02:00 EEST | Press release
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 14:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says Moira Gilchrist, Chief Global Communications Officer at Philip Morris International. “AI can help us work more efficiently, but we need to be careful not to outsource ou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom